Alaunos Therapeutics, Inc.
TCRT
$4.29
$0.2947.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.67% | 80.00% | -60.00% | -99.79% | -99.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.67% | 80.00% | -60.00% | -99.79% | -99.79% |
| Cost of Revenue | -97.56% | -98.48% | -93.13% | -78.93% | -58.25% |
| Gross Profit | 97.66% | 98.53% | 93.16% | 75.84% | 52.34% |
| SG&A Expenses | -66.36% | -63.51% | -52.49% | -30.65% | -16.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -79.71% | -83.08% | -76.18% | -61.53% | -43.25% |
| Operating Income | 79.75% | 83.11% | 76.19% | 58.05% | 38.29% |
| Income Before Tax | 84.79% | 86.68% | 67.68% | 48.06% | 29.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.79% | 86.68% | 67.68% | 48.06% | 29.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.79% | 86.68% | 67.68% | 48.06% | 29.52% |
| EBIT | 79.75% | 83.11% | 76.19% | 58.05% | 38.29% |
| EBITDA | 78.03% | 81.63% | 74.73% | 57.22% | 38.01% |
| EPS Basic | 84.81% | 86.70% | 68.32% | 50.41% | 34.48% |
| Normalized Basic EPS | 80.63% | 84.08% | 78.41% | 63.71% | 45.20% |
| EPS Diluted | 84.81% | 86.70% | 68.92% | 51.32% | 37.00% |
| Normalized Diluted EPS | 80.63% | 84.08% | 78.41% | 63.71% | 45.20% |
| Average Basic Shares Outstanding | 0.06% | 0.11% | 1.89% | 4.64% | 7.51% |
| Average Diluted Shares Outstanding | 0.06% | 0.11% | 1.89% | 4.64% | 7.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |